Altre lingue Theravance Biopharma, Inc.

Azioni

TBPH

KYG8807B1068

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 08/07/2024			Variaz. 5gg	Var. 1 gen.
8,84 ^USD	+0,91%		+3,76%	-21,35%

23/05	Transcript : Theravance Biopharma, Inc. - Special Call
13/05	Theravance riduce la perdita del primo trimestre con un aumento delle entrate; le azioni salgono dopo l'orario di lavoro	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Pharmaceuticals Select Industry Index	24/06
Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours	13/05
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, vs. Street Est of $14M	13/05
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update	13/05
Theravance Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Theravance Biopharma to Participate in an Upcoming Investor Conference	09/05
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024	29/04
Sector Update: Health Care Stocks Lower Friday Afternoon	12/04
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	12/04
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024	10/04
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	01/03
Theravance Bio: Q4 Earnings Snapshot	26/02
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M	26/02
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26/02
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Theravance Biopharma to Participate in an Upcoming Investor Conference	22/02
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	14/02
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint	05/01
Top Premarket Decliners	05/01
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)	05/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Theravance Biopharma, Inc.

Azioni

TBPH

KYG8807B1068

Altre lingue

Filtri